bluebird bio
BLUE
BLUE was delisted on the 30th of May, 2025.
151 hedge funds and large institutions have $228M invested in bluebird bio in 2022 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 54 increasing their positions, 41 reducing their positions, and 45 closing their positions.
32% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 41
0.49% less ownership
Funds ownership: 4.34% → 3.85% (-0.49%)
13% less funds holding
Funds holding: 174 → 151 (-23)
25% less capital invested
Capital invested by funds: $303M → $228M (-$74.9M)
42% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 45
59% less call options, than puts
Call options by funds: $1.84M | Put options by funds: $4.53M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$16.9M |
| 2 |
Renaissance Technologies
New York
|
+$7.25M |
| 3 |
Millennium Management
New York
|
+$6.07M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$3.23M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$3.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$43.9M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$9.39M |
| 3 |
Morgan Stanley
New York
|
-$3.58M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$3.17M |
| 5 |
Rafferty Asset Management
New York
|
-$2.78M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
176
Macquarie Group
Sydney, NSW 2000,
Australia
| – | -$6 | -63 | Closed |
|
|
TWA
177
TCI Wealth Advisors
Tucson,
Arizona
| – | -$4K | -42 | Closed |
|
178
DZ Bank
Frankfurt Am Main,
Germany
| – | -$3.4K | -35 | Closed |
|
|
FFA
179
Freedman Financial Associates
Peabody,
Massachusetts
| – | -$3K | -25 | Closed |
|
|
MPWT
180
MassMutual Private Wealth & Trust
Windsor,
Connecticut
| – | -$2K | -20 | Closed |
|
|
SWM
181
Spire Wealth Management
Mclean,
Virginia
| – | -$2K | -16 | Closed |
|
|
IC
182
Ikarian Capital
Dallas,
Texas
| – | -$1K | -15 | Closed |
|
|
S
183
SignatureFD
Atlanta,
Georgia
| – | -$1K | -13 | Closed |
|
|
GWS
184
Glassman Wealth Services
Vienna,
Virginia
| – | -$1K | -12 | Closed |
|
|
LC
185
Lindbrook Capital
Calabasas,
California
| – | -$698 | -9 | -82% |
|
|
BFEC
186
Benjamin F. Edwards & Company
St. Louis,
Missouri
| – | -$1K | -7 | Closed |
|
|
QCG
187
Quadrant Capital Group
Cincinnati,
Ohio
| – | -$1K | -6 | Closed |
|
|
PA
188
Parallel Advisors
San Francisco,
California
| – | -$155 | -2 | Closed |
|
189
Rockefeller Capital Management
New York
| – | +$310 | +4 | New |
|
BLUE Hedge Fund Activity: Q2 2022 in Review
151 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in bluebird bio (BLUE) for Q2 2022, worth a combined $228M — down 25% from $303M a quarter earlier.
Sellers outnumbered buyers: 45 funds closed out of BLUE and 26 opened new positions — a net loss of 19 holders — while 41 trimmed existing stakes and 54 added.
The largest buyer was Tang Capital Management, adding an estimated $16.9M. The largest seller was State Street, cutting an estimated $43.9M.
- 151 institutional investors held bluebird bio (BLUE) as of Q2 2022, down from 174 in Q1 2022.
- Funds reported $228M of bluebird bio stock for Q2 2022, down 25% quarter-over-quarter.
- 26 funds opened new bluebird bio positions in Q2 2022 and 45 closed out, a net change of -19 holders.
- The largest bluebird bio buyer in Q2 2022 was Tang Capital Management, an estimated $16.9M added.
- The largest bluebird bio seller in Q2 2022 was State Street, an estimated $43.9M sold.
Based on aggregated 13F filings for Q2 2022.